While purchasing medicine - It is important that you let us know what other medicine you are using.
This is for preventing unwanted drug interactions.


Want to ask us a professional question ? Call us or Connect VIA Skype





Skype Me™! 
 



 
 
 
 

CYTARABINE INJECTION
Home >> Search Drug By Letter >> Search Drug By Letter: C >> CYTARABINE INJECTION
Search Drug By Letter : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 CYTARABINE INJECTION
 

Package(a):
VIALS (POWDER FOR INJECTION): 1 x 1 G.
Dosage(a):
See prescribing information for full details.
Prescribing Restrictions:  None

Package(b):
VIALS (POWDER FOR INJECTION): 1 x 2 G.
Dosage(b):
See prescribing information for full details.
Prescribing Restrictions:  None


Indications:
In combination with other approved anticancer drugs for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine is indicated in the prophylaxis and treatment of meningeal leukemia.
Contra-Indications:
Hypersensitivity to the drug.
Special Precautions:
To be administered only by physicians experienced in cancer chemotherapy. Patients should be treated in a facility with laboratory and supportive resources. Therapy should be started cautiously in patients with pre-existing drug-induced bone marrow suppression. Perform leukocyte and platelet counts daily and bone marrow examinations frequently. Consider suspending or modifying therapy when platelet count under 50,000/mm3 or a polymorphonuclear granulocyte count under 1,000/mm3. Restart therapy when definite signs of marrow recovery appear. 
Pregnancy: Can cause fetal harm. 
See prescribing information for full details.
Side Effects:
Thrombophlebitis, hepatic dysfunction, oral and anal inflammation or ulceration, nausea and vomiting (most frequent following rapid I.V. injection), fever, anorexia, bleeding (all sites), diarrhea, rash.
Drug Interactions:
Reversible decreases in steady-state plasma digoxin and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine. Steady-state plasma digitoxin concentrations did not apppear to change. Monitoring of plasma digoxin levels may be indicated in patients receiving similar combination chemotherapy regimens. The utilization of digitoxin for such patients may be considered as an alternative.